Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Maxygen, Inc. (Nasdaq: MAXY), a biopharmaceutical company, today announced financial and business results for the quarter ended March 31, 2013.
Maxygen reported a net loss of $2.1 million, or $0.08 per basic and diluted share, for the first quarter of 2013, compared to a net loss of $2.6 million, or $0.09 per basic and diluted share, for the same period in 2012.
Help employers find you! Check out all the jobs and post your resume.
